Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19
SourceJAMA Network Open, 3, 8, (2020), article e2017708
Article / Letter to editor
Display more detailsDisplay less details
JAMA Network Open
SubjectRadboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences; Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences
This case-control study examines the association between receipt of the bradykinin 2 (B2) receptor antagonist icatibant and improved oxygenation in patients with coronavirus disease 2019 (COVID-19).
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.